Abstract
SM-101 is a mixture of metampicillin and sulbactam(2∶1). The antibacterial activities of SM-101 were compared with those of metampicillin, piperacillin and Augmentin. It showed powerful antibacterial activities against major strains. ExceptP. aeruginosa andS. marcescens, thein vitro antibacterial activity of SM-101 was higher than those of metampicillin, piperacillin and Augmentin againstStaphylococcus spp.,Streptococcus spp.,Morganella morganii, E. coli, andProteus spp. The ED50 values of SM-101 were two-fold or greater than those of metampicillin, piperacillin and Augmentin against β-lactamase producing strains,P. mirabilis GN 79 andM. morganii MB4-11. Thein vivo efficacy of SM-101 was more active than metampicillin and piperacillin and similar to Augmentin againstS. aureus Smith,E. coli MB4-01 andK. pneumoniae MB4-02.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Chong, Y. S. and Lee, S. Y., Comparative activities of cefoperazone and cefoperazone plus sulbactam (sulperazone) against clinical isolates of Gram negativeBacilli.J. Kor. Soc. Chemother., 7, 40–46 (1989).
Cleeland, R. and Squires, E., Evaluation of new antimicrobials in vitro and in experimental animal infection.Antibiotics in laboratory medicine, 3 rd ed. (Lorian, V), pp 739–786. Williams & Wilkins, Bultimore (1991).
Fass, R. J. and Prior, R. B., Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.Antimicrobial agents and Chemother., 33, 1268–1274 (1989).
Goto, S., Ogawa, M., Kaneto, Y., Miyazakin, S., Tsuji, A. and Kuwahara, S., Bacteriological studies on sultamicillin.Chemother., 33 (S-2): 37–53 (1985).
Greenwood, D. and Eley, A., In vitro evaluation of sulbactam, a penicillanic acid sulphone with β-lactamase inhibitory properties.J. Antimicrob. Chemother., 10, 117–123 (1982).
Japan Soceity of Chemotherapy. Committee report.Chemother., (Tokyo) 29: 76–79 (1989).
Jones, N. and Barry, A. L., Studies on optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).Rev. Microbiol. Infec. Dis., 12, 495–510 (1989).
Kim, Y. S., USA Pat. No. 5,049,384. Antibacterial composition for medical use and a process for the preparation thereof (1991).
Kuck, N. A., Jacobus, N. V., petersen, P. J., Weiss, W. J., and Testa R. T., Comparativein vitro andin vivo activities of piperacillin combined with β-lactamase inhibitors tazobactam, clavulanic acid and sulbactam.Antimicrob. Agents Chemother., 33, 1964–1969 (1989).
Litchfield, J. T. and Wilcoxon, F. A., A simplified method of evaluating dose-effect experiments.J. Pharmacol. Exp. and Ther., 96, 99–103 (1949).
Nakazawa H., Mastura, M. and Mitsuhashi S., -lactamase inhibitory effect of clavulanic acid and antibacterial activity of BRL 25000 (clavulanic acid-amoxicillin).Chemother., 30(S-2): 1–10 (1982).
Suginaka H., and Miyake Y., Effects of a combination of clavulanic acid and amoxicillin on peptidoglycan synthesis in β-lactamase producingE. coli.Chemother., 30(S-2): 76–80 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Choi, KH., Kim, SK., Baek, MC. et al. In vitro andin vivo activities of SM-101, a mixture of metampicillin and sulbactam. Arch. Pharm. Res. 18, 423–426 (1995). https://doi.org/10.1007/BF02976346
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976346